Q BioMed Inc (QBIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
38
About the Report
About the Report
Summary
Q BioMed Inc (Q BioMed), formerly ISMO Tech Solutions Inc, is a biomedical acceleration and development company. The company offers Strontium Chloride SR89, a radiopharmaceutical agent for the treatment of pain associated with metastatic bone cancer. It develops Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for pediatric developmental nonverbal disorder; and UTTROSIDE-B Chemotherapeutic, UTTROSIDE-B chemotherapeutic, a natural compound for the treatment for variety of liver cancer cell types. The company has partnership with Sphaera Pharma to develop an analog of QBM-001 for pediatric developmental nonverbal disorder. Q BioMed is headquartered in New York, the US.
Q BioMed Inc (QBIO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Q BioMed Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Q BioMed Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Q BioMed Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Q BioMed to Acquire Assets of Mannin Research 11
Partnerships 12
Q BioMed Enters into Agreement with Sphaera Pharma 12
Q BioMed Enters into Agreement with Oklahoma Medical Research Foundation and Rajiv Gandhi Centre for Biotechnology 13
Licensing Agreements 14
Q BioMed to Expand Option Agreement with Washington University 14
Q BioMed Enters into Licensing Agreement with Oklahoma Medical Research Foundation and Rajiv Gandhi Centre for Biotechnology 15
Q Biomed Enters into Licensing Agreement with Asdera 16
Q BioMed Amends its Licensing Agreement with Bio-Nucleonics 17
Q BioMed Enters into Option Agreement to Acquire Platform Technology Assets of Mannin Research 18
Equity Offering 19
Q BioMed Raises USD5.5 Million in Public Offering of Shares 19
Q BioMed Raises USD3 Million in Private Placement of Units 20
Q BioMed Plans to Raise Funds through Public Offering of Shares 21
Q BioMed Withdraws Public Offering of Shares for USD9.59 million 22
Q BioMed Raises Funds in Private Placement of Units 23
Q BioMed Raises USD0.1 Million in Private Placement of Units 24
Q BioMed Raises Funds in Private Placement of Units 25
Q BioMed Raises Funds in Private Placement of Units 26
Debt Offering 27
Q BioMed Raises USD1.5 Million in Final Tranche of Private Placement of 5% Debentures Due 2017 27
Q BioMed Raises USD1 Million in Second Tranche of Private Placement of 5% Debentures Due 2017 28
Q BioMed Raises USD1.5 Million in First Tranche Private Placement of 5% Debentures Due 2017 29
Q BioMed Inc-Key Competitors 30
Q BioMed Inc-Key Employees 31
Q BioMed Inc-Locations And Subsidiaries 32
Head Office 32
Recent Developments 33
Corporate Communications 33
Sep 17, 2018: Q Biomed names Dr. Rajendra Apte to advisory board 33
Feb 13, 2018: Q BioMed Adds Dr. Rick Panicucci to Board of Directors 34
Product News 35
Dec 21, 2017: Q BioMed Provides Year End Update 35
Other Significant Developments 37
Jun 06, 2018: Q BioMed Provides Important Update on Mannin Research Tie2 Technology Platform Development 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38
List of Figure
List of Figures
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
Q BioMed Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Q BioMed Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Q BioMed Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Q BioMed to Acquire Assets of Mannin Research 11
Q BioMed Enters into Agreement with Sphaera Pharma 12
Q BioMed Enters into Agreement with Oklahoma Medical Research Foundation and Rajiv Gandhi Centre for Biotechnology 13
Q BioMed to Expand Option Agreement with Washington University 14
Q BioMed Enters into Licensing Agreement with Oklahoma Medical Research Foundation and Rajiv Gandhi Centre for Biotechnology 15
Q Biomed Enters into Licensing Agreement with Asdera 16
Q BioMed Amends its Licensing Agreement with Bio-Nucleonics 17
Q BioMed Enters into Option Agreement to Acquire Platform Technology Assets of Mannin Research 18
Q BioMed Raises USD5.5 Million in Public Offering of Shares 19
Q BioMed Raises USD3 Million in Private Placement of Units 20
Q BioMed Plans to Raise Funds through Public Offering of Shares 21
Q BioMed Withdraws Public Offering of Shares for USD9.59 million 22
Q BioMed Raises Funds in Private Placement of Units 23
Q BioMed Raises USD0.1 Million in Private Placement of Units 24
Q BioMed Raises Funds in Private Placement of Units 25
Q BioMed Raises Funds in Private Placement of Units 26
Q BioMed Raises USD1.5 Million in Final Tranche of Private Placement of 5% Debentures Due 2017 27
Q BioMed Raises USD1 Million in Second Tranche of Private Placement of 5% Debentures Due 2017 28
Q BioMed Raises USD1.5 Million in First Tranche Private Placement of 5% Debentures Due 2017 29
Q BioMed Inc, Key Competitors 30
Q BioMed Inc, Key Employees 31
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.